Abstract:Development of an effective vaccine to target tumor associated carbohydrate antigens, aberrantly expressed on the cell surface of various carcinomas, is an appealing approach toward cancer immunotherapy. However, a major problem of carbohydrate antigens is their poor immunogenicity. Immunization with modified-carbohydrate antigens could improve the immunogenicity and induce cross reaction with the native carbohydrate antigens. In this study, we investigated the antitumor ability of three fluoro-substituted sialyl-Tn (STn) analogues (2, 3, 4) coupled to KLH (keyhole limpet hemocyanin) and studied the mechanism of tumor immunotherapy of the vaccines in a murine model of colon cancer. Vaccination with 4-KLH, in which the two N-acetyl groups of STn are substituted with N-fluoroacetyl groups, could remarkably prolong the survival of tumor-bearing mouse and resulted in a significant reduction in tumor burden of lungs compared with STn-KLH (1-KLH). The vaccine 4-KLH could provoke stronger cytotoxic T lymphocytes immune response, T helper (Th) cell-mediated immune response and an earlier-stage Th1 immune response than 1-KLH, thus breaking immune tolerance and generating a therapeutic response. The 4-KLH vaccine induced strong tumor-specific anti-STn antibodies which could mediate complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity against human tumor cells. Moreover, in the absence of adjuvant, 4-KLH still elicited stronger immune responses than 1-KLH. Our data suggested that 4-KLH is superior in tumor prevention. The strategic hapten fluorination may be a potential approach applicable to the vaccines development for the cancer immunotherapy.

Tumor-Associated Extracellular Microvesicles with Fluorine-Modified Carbohydrate Antigens Trigger a Stronger Antitumor Immune Response

Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes.

Glycosylation in the Tumor Immune Response: the Bitter Side of Sweetness

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Tumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy

Carbohydrate-based cancer vaccines: target cancer with sugar bullets

A Cancer Vaccine Based on Fluorine-Modified Sialyl-Tn Induces Robust Immune Responses in a Murine Model

Radiation-induced small extracellular vesicles as “carriages” promote tumor antigen release and trigger antitumor immunity

[Recent Advance in Carbohydrate-Based Cancer Vaccines].

Tumor-derived microvesicles for cancer therapy

Multivalent Carbohydrate Nanocomposites for Tumor Microenvironment Remodeling to Enhance Antitumor Immunity

Liposome-Based Carbohydrate Vaccine for Simultaneously Eliciting Humoral and Cellular Antitumor Immunity

Recent advance in carbohydrate-based cancer vaccines]

Extracellular vesicles derived from immune cells: Role in tumor therapy

Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy

Extracellular vesicles remodel tumor environment for cancer immunotherapy

Carbohydrate‐based Vaccines for Oncotherapy

Tumor-Derived Extracellular Vesicles Regulate Cancer Progression in the Tumor Microenvironment

Modulatory effects of cancer stem cell-derived extracellular vesicles on the tumor immune microenvironment

Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?

Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate